A landmark six-year study involving over 2,000 patients at 28 institutions demonstrates that next-generation sequencing of ERCP-obtained specimens achieves 82% sensitivity for neoplastic bile duct strictures, nearly doubling traditional pathology's 44% sensitivity while maintaining 98% specificity.